Major depressive disorder is the most widespread mood disorder in the world. Also called clinical depression, or just depression, it's when you have symptoms of low mood or hopelessness for at ...

References: Fabre-Kramer Pharmaceuticals announces FDA approval of Exxua™, the first and only oral selective 5HT1a receptor agonist for the treatment of major depressive disorder in adults.

If you have been diagnosed with major depressive disorder, you’ll want to get treatment as soon as possible.To get the care you need, it’s important you find a specialist that fits your needs.

Fabre-Kramer Submits NDA Amendment for EXXUA™ for Treatment of Major Depressive Disorder. News Release. Fabre-Kramer. January 24, 2023.

Neumora Therapeutics Inc.’s stock tumbled 81% Thursday after the clinical-stage biotech said a late-stage trial of a treatment for major depressive disorder failed to meet its main goals.

The Multiple Layers of Major Depressive Disorder Management: Unravelling the Who, When, and How for Antidepressant Modification 0.75 CME / CE / ABIM MOC Credits You are being redirected to ...

Zhdanava M et al. Esketamine Nasal Spray for Major Depressive Disorder With Acute Suicidal Ideation or Behavior: Description of Treatment Access, Utilization, and Claims-Based Outcomes in the ...

The Food and Drug Administration (FDA) has approved Spravato, a novel nasal spray, for the standalone treatment of major depressive disorder (MDD), post-traumatic stress disorder (PTSD), and other ...

Payers provide insights to health care disparities currently impacting patients with major depressive disorder (MDD). ... Aligning MDD Treatment Goals for Payers and Patients. EP: 19.

The Ratings Game This biotech’s stock could double if its treatment for major depressive disorder succeeds, says Mizuho It’s been 30 years since a novel mechanism of action was approved for ...

“Unspecified depressive disorder” is used when someone displays depressive symptoms, but there isn’t enough information for a specific diagnosis. Depressive symptoms can be complex and may ...

Neumora Therapeutics Inc.'s stock tumbled 81% Thursday after the clinical-stage biotech said a late-stage trial of a treatment for major depressive disorder failed to meet its main goals.